{"id":"https://openalex.org/W2139575022","doi":"https://doi.org/10.1128/aac.00833-06","title":"Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present","display_name":"Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present","publication_year":2006,"publication_date":"2006-12-19","ids":{"openalex":"https://openalex.org/W2139575022","doi":"https://doi.org/10.1128/aac.00833-06","mag":"2139575022","pmid":"https://pubmed.ncbi.nlm.nih.gov/17178796","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/1803124"},"language":"en","primary_location":{"id":"doi:10.1128/aac.00833-06","doi":"https://doi.org/10.1128/aac.00833-06","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.00833-06","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1803124","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019122233","display_name":"Daniel J. Tenney","orcid":"https://orcid.org/0000-0002-0315-5820","observed_orcids":["https://orcid.org/0000-0002-0315-5820"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel J. Tenney","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","Bristol-Myers Squibb Pharmaceutical Research Inst., 5 Research Parkway, Wallingford, CT 06492, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]},{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Inst., 5 Research Parkway, Wallingford, CT 06492, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108424170","display_name":"Ronald E. Rose","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald E. Rose","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110186945","display_name":"Carl J. Baldick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carl J. Baldick","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Steven M. Levine","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Steven M. Levine","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111947341","display_name":"Kevin A. Pokornowski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin A. Pokornowski","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018674792","display_name":"Ann W. Walsh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann W. Walsh","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113293873","display_name":"Jie Fang","orcid":"https://orcid.org/0009-0004-6436-0555","observed_orcids":["https://orcid.org/0009-0004-6436-0555"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jie Fang","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014720387","display_name":"Cheng-Fang Yu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cheng-Fang Yu","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031672504","display_name":"Sharon Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sharon Zhang","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079268137","display_name":"Charles E. Mazzucco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles E. Mazzucco","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108454990","display_name":"Betsy J. Eggers","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Betsy Eggers","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109972065","display_name":"Mayla Hsu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mayla Hsu","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067395186","display_name":"Mary Jane Plym","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary Jane Plym","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036673594","display_name":"Patricia Poundstone","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia Poundstone","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109972424","display_name":"Joanna Y. Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joanna Yang","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036974423","display_name":"Richard J. Colonno","orcid":"https://orcid.org/0000-0001-5381-3716","observed_orcids":["https://orcid.org/0000-0001-5381-3716"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard J. Colonno","raw_affiliation_strings":["Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492","institution_ids":["https://openalex.org/I4210091812"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210091812"],"apc_list":null,"apc_paid":null,"fwci":20.7275,"has_fulltext":false,"cited_by_count":235,"citation_normalized_percentile":{"value":0.99591809,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"51","issue":"3","first_page":"902","last_page":"911"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10340","display_name":"Hepatitis B Virus Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10340","display_name":"Hepatitis B Virus Studies","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/entecavir-resistance","display_name":"entecavir resistance","score":0.9520000219345093},{"id":"https://openalex.org/keywords/lamivudine-resistance","display_name":"lamivudine resistance","score":0.9229999780654907},{"id":"https://openalex.org/keywords/hepatitis-b-virus","display_name":"hepatitis B virus","score":0.9940000176429749},{"id":"https://openalex.org/keywords/chronic-hepatitis-b","display_name":"chronic hepatitis B","score":0.6349999904632568},{"id":"https://openalex.org/keywords/virological-rebound","display_name":"virologic rebound","score":0.8270000219345093},{"id":"https://openalex.org/keywords/antiviral-resistance","display_name":"antiviral resistance","score":0.6840000152587891}],"concepts":[{"id":"https://openalex.org/C2776175608","wikidata":"https://www.wikidata.org/wiki/Q418586","display_name":"Entecavir","level":5,"score":0.932532012462616},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.8777825832366943},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.6713376045227051},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.6564247608184814},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5811006426811218},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.5494241118431091},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5211268067359924},{"id":"https://openalex.org/C51296783","wikidata":"https://www.wikidata.org/wiki/Q1645498","display_name":"Microgram","level":3,"score":0.49447154998779297},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.47690391540527344},{"id":"https://openalex.org/C2777382497","wikidata":"https://www.wikidata.org/wiki/Q6853","display_name":"Hepatitis B","level":2,"score":0.44770175218582153},{"id":"https://openalex.org/C140704245","wikidata":"https://www.wikidata.org/wiki/Q3933202","display_name":"Viral replication","level":3,"score":0.4452294111251831},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4294048547744751},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.41607195138931274},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.344319224357605},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.2328777015209198},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.12627723813056946},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07739800214767456},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D002478","descriptor_name":"Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004259","descriptor_name":"DNA-Directed DNA Polymerase","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D004279","descriptor_name":"DNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006147","descriptor_name":"Guanine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D006147","descriptor_name":"Guanine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006147","descriptor_name":"Guanine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D006509","descriptor_name":"Hepatitis B","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D006509","descriptor_name":"Hepatitis B","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D006515","descriptor_name":"Hepatitis B virus","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D006515","descriptor_name":"Hepatitis B virus","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010957","descriptor_name":"Plasmids","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D014779","descriptor_name":"Virus Replication","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D024882","descriptor_name":"Drug Resistance, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1128/aac.00833-06","doi":"https://doi.org/10.1128/aac.00833-06","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.00833-06","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:1803124","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1803124","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:17178796","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17178796","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Journal Article"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:1803124","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/1803124","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8299999833106995,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":41,"referenced_works":["https://openalex.org/W1511455589","https://openalex.org/W1970030713","https://openalex.org/W1972613143","https://openalex.org/W1973276254","https://openalex.org/W1982960788","https://openalex.org/W1985577568","https://openalex.org/W1985860298","https://openalex.org/W1987843876","https://openalex.org/W1990584242","https://openalex.org/W2009185691","https://openalex.org/W2011956157","https://openalex.org/W2014279976","https://openalex.org/W2014837723","https://openalex.org/W2033630039","https://openalex.org/W2045347800","https://openalex.org/W2052700689","https://openalex.org/W2065099361","https://openalex.org/W2074328423","https://openalex.org/W2091228258","https://openalex.org/W2094364729","https://openalex.org/W2104969243","https://openalex.org/W2108147025","https://openalex.org/W2112150016","https://openalex.org/W2112861457","https://openalex.org/W2114002124","https://openalex.org/W2116148860","https://openalex.org/W2123543307","https://openalex.org/W2124012164","https://openalex.org/W2125023549","https://openalex.org/W2126563189","https://openalex.org/W2126983724","https://openalex.org/W2127912984","https://openalex.org/W2131213171","https://openalex.org/W2143375642","https://openalex.org/W2143584498","https://openalex.org/W2144084705","https://openalex.org/W2149498593","https://openalex.org/W2155154284","https://openalex.org/W2334098978","https://openalex.org/W2393327590","https://openalex.org/W4230614946"],"related_works":["https://openalex.org/W2123543307","https://openalex.org/W2332883206","https://openalex.org/W2126563189","https://openalex.org/W2047160864","https://openalex.org/W2068945527","https://openalex.org/W1976104517","https://openalex.org/W3147621671","https://openalex.org/W2067560542","https://openalex.org/W7099048727","https://openalex.org/W7132503879"],"abstract_inverted_index":{"Entecavir":[0],"(ETV)":[1],"is":[2],"a":[3,156,177,255,270,286],"deoxyguanosine":[4],"analog":[5],"approved":[6],"for":[7,9,87,100],"use":[8,154],"the":[10,36,164,180,232,248,283],"treatment":[11],"of":[12,38,48,132,155,163,179,272,282],"chronic":[13],"infection":[14],"with":[15,97,103,209,226,265,279],"wild-type":[16],"and":[17,46,53,75,134,142,150,188,230,278],"lamivudine-resistant":[18],"(LVDr)":[19],"hepatitis":[20],"B":[21],"virus":[22],"(HBV).":[23],"In":[24,257],"LVD-refractory":[25,263],"patients,":[26,264],"1.0":[27],"mg":[28],"ETV":[29,64,243,251,259],"suppressed":[30],"HBV":[31,70,127],"DNA":[32],"levels":[33],"to":[34,63,109,250],"below":[35],"level":[37],"detection":[39],"by":[40,50,147],"PCR":[41,159],"(<300":[42],"copies/ml)":[43],"in":[44,107,125,130,136,182,196,206,218,254,262],"21%":[45],"34%":[47],"patients":[49,94,113,133,146,202,214,225,273,284],"Weeks":[51,148],"48":[52,149],"96,":[54,151],"respectively.":[55,152],"Prior":[56],"studies":[57],"showed":[58],"that":[59,170],"virologic":[60,115,287],"rebound":[61],"due":[62],"resistance":[65],"(ETVr)":[66],"required":[67],"preexisting":[68,275],"LVDr":[69,126,229],"reverse":[71],"transcriptase":[72],"substitutions":[73,240],"M204V":[74],"L180M":[76],"plus":[77],"additional":[78,211],"changes":[79,166,181],"at":[80,128,167],"T184,":[81,118],"S202,":[82,119],"or":[83,120,252],"M250.":[84],"To":[85],"monitor":[86],"resistance,":[88],"available":[89],"isolates":[90,102,110,137,184,191],"from":[91,111,138,222,269],"192":[92],"ETV-treated":[93,145],"were":[95,192,228],"sequenced,":[96],"phenotyping":[98],"performed":[99],"all":[101,104,112,190,223],"emerging":[105,165],"substitutions,":[106],"addition":[108],"experiencing":[114,215,285],"rebounds.":[116],"The":[117],"M250":[121],"substitution":[122],"was":[123,260],"found":[124],"baseline":[129],"6%":[131],"emerged":[135,241],"another":[139],"11/187":[140],"(6%)":[141],"12/151":[143],"(8%)":[144],"However,":[153],"more":[157],"sensitive":[158],"assay":[160],"detected":[161],"many":[162],"baseline,":[168],"suggesting":[169],"they":[171],"originated":[172],"during":[173,242],"LVD":[174],"therapy.":[175],"Only":[176],"subset":[178,271],"ETVr":[183,204,216],"altered":[185],"their":[186],"susceptibilities,":[187],"virtually":[189],"significantly":[193],"replication":[194],"impaired":[195],"vitro.":[197],"Consequently,":[198],"only":[199],"2/187":[200],"(1%)":[201],"experienced":[203],"rebounds":[205,217,227],"year":[207,219],"1,":[208],"an":[210],"14/151":[212],"(9%)":[213],"2.":[220],"Isolates":[221],"16":[224],"harbored":[231],"T184":[233],"and/or":[234],"S202":[235],"change.":[236],"Seventeen":[237],"other":[238],"novel":[239],"therapy,":[244],"but":[245],"none":[246],"reduced":[247],"susceptibility":[249],"resulted":[253],"rebound.":[256,288],"summary,":[258],"effective":[261],"resistant":[266],"sequences":[267],"arising":[268],"harboring":[274],"LVDr/ETVr":[276],"variants":[277],"approximately":[280],"half":[281]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":8},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":8},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":10},{"year":2013,"cited_by_count":17},{"year":2012,"cited_by_count":19}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}